The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
European Renal Association 59th Annual Meeting May 19–22, 2022
Presentations of the Bayer Industry Symposium at the European Renal Association 59th Annual Meeting Annual Meeting 2022
Thank you for your interest! Please see below to download PDFs of the presentation of the Bayer Industry Symposia at the ERA Congress 2022, chaired by Patrick Rossignol, with presentations from Jolanta Malyszko, Roland Schmieder and George Bakris.
Access to the presentations will be available after the congress presentation.
Finerenone
Saturday 21 May, 2022 | 13:35 - 13:50 CEST
Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D
CKD in T2D: How urgently do we heed the call for treatment?
Session: Industry Symposium Speaker: Jolanta Malyszko
Saturday 21 May, 2022 | 13:35 - 13:50 CEST
Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D
Cardiorenal protection in patients with CKD and T2D: From FIDELIO-DKD to FIDELITY
Session: Industry Symposium Speaker: Roland Schmieder
Saturday 21 May, 2022 | 13:35 - 13:50 CEST
Nonsteroidal MRAs: A new hope for improved cardiorenal outcomes in patients with CKD and T2D
Nonsteroidal MRAs in clinical practice: Whom to treat, when and how
Session: Industry Symposium Speaker: George Bakris
MA-M_FIN-ALL-0850-1